TORPEDO: Prospective, double blind, randomized clinical trial comparing the use of Ketorolac verse placebo during live donor nephrectomy for kidney transplant

• Published in: Transplantation reports 2017-06, Vol.2 (2), p.11-13
• Main Authors: Campsen, Jeffrey, Call, Tyler, Thiesset, Heather F, Rosales, Alec, Kim, Robin D
• Format: Article
• Language: English
• Subjects: Kidney transplant; Live donor; Narcotic; Nephrectomy; Surgery
• ISSN: 2451-9596; 2451-9596
• DOI: 10.1016/j.tpr.2017.05.002

Abstract The aim of this pilot study was to determine if the use of Ketorolac for donor nephrectomies could decrease the use of narcotics. Methods: This is a prospective, double blind, randomized trial involving patients undergoing nephrectomy for live donor kidney transplantation. Three arms: 1. Ketorolac 30 mg IV x 1 in the OR, then ketorolac 15 mg IV every 6 hours for 7 doses. 2. Ketorolac 30 mg IV x 1 in the OR, then placebo IV every 6 hours for 7 doses. 3. Placebo IV x 1 in the OR, then placebo IV every 6 hours for 7 doses. Outcomes: blood loss, mortality, renal function, cumulative narcotic use, length of hospital stay (LOS), and urinary retention. Results: There were no patient deaths, blood transfusions or renal dysfunction in any study arm. Arm 1 had less narcotic use, reduced length of stay, and reduced urinary retention than Arm 3. Conclusion: There was reduced LOS, less narcotic use and less urinary retention in the Ketorolac group (Arm 1) versus the placebo group (Arm 3). Based on these results we will proceed with a larger study to compare the use of non-opioid analgesics in donor nephrectomies.